Tumour response after hyperthermic isolated limb perfusion for locally advanced melanoma
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Tumour response after hyperthermic isolated limb perfusion for locally advanced melanoma. / Paulsen, Ida Felbo; Chakera, A H; Drejøe, Jennifer Berg; Klyver, Helle; Dahlstrøm, Karin; Oturai, Peter Sandor; Mortensen, Jann; Hesse, Birger; Schmidt, Grethe; Drzewiecki, Krzysztof.
I: Danish Medical Journal, Bind 61, Nr. 1, A4741, 01.2014.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Tumour response after hyperthermic isolated limb perfusion for locally advanced melanoma
AU - Paulsen, Ida Felbo
AU - Chakera, A H
AU - Drejøe, Jennifer Berg
AU - Klyver, Helle
AU - Dahlstrøm, Karin
AU - Oturai, Peter Sandor
AU - Mortensen, Jann
AU - Hesse, Birger
AU - Schmidt, Grethe
AU - Drzewiecki, Krzysztof
PY - 2014/1
Y1 - 2014/1
N2 - INTRODUCTION: The aim was to describe tumour response, complications, recurrence and survival after hyperthermic isolated limb perfusion (ILP) with melphalan or melphalan in combination with tumour necrosis factor-alpha in patients with melanoma metastases confined to an extremity.MATERIAL AND METHODS: A total of 84 perfusions were performed (53 women, 31 men, median age 63 years) from 1993 to 2010. 95% of the perfusions were administered to the lower limbs and 5% to the upper limbs. The inclusion criteria were recurrent and/or clinically apparent cutaneous/subcutaneous extremity in-transit melanoma metastases.RESULTS: The response rate after ILP was 85%; 42% had complete response (CR), 43% partial response (PR), 12% no change (NC) and 3% progression. Two- and five-year survival rates were 57% and 31%, respectively, and they were higher for patients with than without lymph node metastases. Time from ILP to recurrence was a median of seven months (range 1-37 months) for patients with CR or PR. Survival was longer for patients with CR or PR than for patients showing NC or progression. Several patients had mild or moderate local toxicity reactions, two patients developed severe local toxicity.CONCLUSION: ILP induces tumour regression in the vast majority of patients. One patient, i.e. 1% of the group, died from surgical complications. Otherwise, ILP treatment had an acceptable morbidity in this group of very sick patients. We are convinced that the treatment should be offered to improve local disease control in patients with multiple and/or recurrent melanoma confined to an extremity if surgical excision is not possible.FUNDING: not relevant.TRIAL REGISTRATION: not relevant.
AB - INTRODUCTION: The aim was to describe tumour response, complications, recurrence and survival after hyperthermic isolated limb perfusion (ILP) with melphalan or melphalan in combination with tumour necrosis factor-alpha in patients with melanoma metastases confined to an extremity.MATERIAL AND METHODS: A total of 84 perfusions were performed (53 women, 31 men, median age 63 years) from 1993 to 2010. 95% of the perfusions were administered to the lower limbs and 5% to the upper limbs. The inclusion criteria were recurrent and/or clinically apparent cutaneous/subcutaneous extremity in-transit melanoma metastases.RESULTS: The response rate after ILP was 85%; 42% had complete response (CR), 43% partial response (PR), 12% no change (NC) and 3% progression. Two- and five-year survival rates were 57% and 31%, respectively, and they were higher for patients with than without lymph node metastases. Time from ILP to recurrence was a median of seven months (range 1-37 months) for patients with CR or PR. Survival was longer for patients with CR or PR than for patients showing NC or progression. Several patients had mild or moderate local toxicity reactions, two patients developed severe local toxicity.CONCLUSION: ILP induces tumour regression in the vast majority of patients. One patient, i.e. 1% of the group, died from surgical complications. Otherwise, ILP treatment had an acceptable morbidity in this group of very sick patients. We are convinced that the treatment should be offered to improve local disease control in patients with multiple and/or recurrent melanoma confined to an extremity if surgical excision is not possible.FUNDING: not relevant.TRIAL REGISTRATION: not relevant.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Antineoplastic Agents
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Chemotherapy, Cancer, Regional Perfusion
KW - Combined Modality Therapy
KW - Disease Progression
KW - Extremities
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Hyperthermia, Induced
KW - Lymphatic Metastasis
KW - Male
KW - Melanoma
KW - Melphalan
KW - Middle Aged
KW - Prospective Studies
KW - Skin Neoplasms
KW - Survival Rate
KW - Treatment Outcome
KW - Tumor Necrosis Factor-alpha
M3 - Journal article
C2 - 24393586
VL - 61
JO - Danish Medical Journal
JF - Danish Medical Journal
SN - 2245-1919
IS - 1
M1 - A4741
ER -
ID: 138217560